Fig. 7: Neutralization of GP73 attenuates ASGR1 deficiency-induced liver injury.

a Schematic diagram of mice treatment. 8-week-old Asgr1^−/− and WT mice were intraperitoneally injected with CCl4 (1 ml/kg body weight, twice a week for 6 weeks). During the last 4 weeks, mice were received either anti-GP73 (10 mg/kg body weight, twice a week for 4 weeks) or IgG. b Serum levels of ALT (n = 6 per group; CCl4+IgG+WT vs. CCl4+IgG+Asgr1^−/−, P = 0.00000018; CCl4+IgG+WT vs. CCl4+anti-GP73 + WT, P = 0.0148; CCl4+anti-GP73 + WT vs. CCl4+anti-GP73+Asgr1^−/−, P = 0.9798). c Serum levels of AST (n = 6 per group; CCl4+IgG+WT vs. CCl4+IgG+Asgr1^−/−, P = 0.0001; CCl4+IgG+WT vs. CCl4+anti-GP73 + WT, P = 0.0015; CCl4+anti-GP73 + WT vs. CCl4+anti-GP73+Asgr1^−/−, P = 0.9969). d H&E staining, Sirius red staining and Masson’s trichrome staining of liver sections. Scale bars, 50 μm. e Schematic diagram of mice treatment. 8-week-old Asgr1^−/− and WT mice were intraperitoneally injected with anti-GP73 (10 mg/kg body weight) or IgG at 10 hours after APAP injection (400 mg/kg body weight). f Serum levels of ALT (n = 6 per group; APAP+IgG+WT vs. APAP+IgG+Asgr1^−/−, P = 0.0047; APAP+IgG+WT vs. APAP+anti-GP73 + WT, P = 0.0001; APAP+anti-GP73 + WT vs. APAP+anti-GP73+Asgr1^−/−, P = 0.9337). g Serum levels of AST (n = 6 per group; APAP+IgG+WT vs. APAP+IgG+Asgr1^−/−, P = 0.000068; APAP+IgG+WT vs. APAP+anti-GP73 + WT, P = 0.0016; APAP+anti-GP73 + WT vs. APAP+anti-GP73+Asgr1^−/−, P = 0.9999). h H&E staining of liver sections. Scale bars, 100 μm. Necrotic areas were encircled. Data are presented as mean ± SEM. P values were calculated by two-way ANOVA with Tukey’s multiple comparison test. *P < 0.05, **P < 0.01. Source data are provided as a Source Data file.